Detalles de la búsqueda
1.
Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial.
Lancet Oncol
; 24(3): 213-227, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36796394
2.
Testosterone replacement in young male cancer survivors: A 6-month double-blind randomised placebo-controlled trial.
PLoS Med
; 16(11): e1002960, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31714912
3.
NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma.
EClinicalMedicine
; 60: 102015, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37287870
4.
Feasibility Study on Using Dynamic Contrast Enhanced MRI to Assess the Effect of Tyrosine Kinase Inhibitor Therapy within the STAR Trial of Metastatic Renal Cell Cancer.
Diagnostics (Basel)
; 11(7)2021 Jul 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-34359384
5.
NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC).
BMJ Open
; 10(2): e034527, 2020 02 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32029495
6.
Results of the SEL-I-METRY Phase II Trial on Resensitization of Advanced Iodine Refractory Differentiated Thyroid Cancer to Radioiodine Therapy.
Thyroid
; 33(9): 1119-1123, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37565288
Resultados
1 -
6
de 6
1
Próxima >
>>